SILVER SPRING, Md., Nov. 1, 2012 /PRNewswire/ -- United Therapeutics Corporation (UTHR) today announced its financial results for the third quarter ended September 30, 2012.
“It is certainly gratifying to see us closely approach, for the first time, a revenue run rate of one billion dollars per year,” said Martine Rothblatt, Ph.D., United Therapeutics’ Chairman and Chief Executive Officer. “Our free cash flow enables us to continue investing in new therapies such as once-daily injectable treprostinil and once-monthly refillable implantable treprostinil that hold great promise for positively transforming the lives of patients with pulmonary arterial hypertension.”
